Literature DB >> 20607643

Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors.

Karen L Wilson1, Craig M Zelig, John P Harvey, Bethany S Cunningham, Brad M Dolinsky, Peter G Napolitano.   

Abstract

We sought to determine if maternal use of selective serotonin reuptake inhibitors (SSRIs) in the second half of pregnancy is associated with persistent pulmonary hypertension of the newborn (PPHN). We performed a case-controlled study (1:6 ratio) of infants delivered at Madigan Army Medical Center with primary PPHN from 2003 through 2009. Study and control patients were compared for the following clinical factors: SSRI use after 20 weeks gestation, mode of delivery, maternal disease, body mass index, tobacco use, fetal gender, maternal age, and parity. We identified 20 cases of primary PPHN out of 11,923 births for an incidence of 0.17%. Mode of delivery was the only factor we found to be associated with PPHN. Specifically, cesarean delivery (CD) prior to the onset of labor increased the risk for PPHN: odds ratio (OR) = 4.9, confidence interval (CI) 1.7 to 14.0. Importantly, use of SSRIs in the second half of pregnancy was identified in 5% of the controls but none of the cases (OR = 0, CI 0 to 3). PPHN is associated with CD prior to the onset of labor but not with SSRI use in the second half of pregnancy. Previous studies linking PPHN to SSRI use relied on after-the-fact patient interviews and incomplete records. Additional studies are needed to verify these results. Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607643     DOI: 10.1055/s-0030-1262507

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  27 in total

1.  Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.

Authors:  Krista F Huybrechts; Brian T Bateman; Kristin Palmsten; Rishi J Desai; Elisabetta Patorno; Chandrasekar Gopalakrishnan; Raisa Levin; Helen Mogun; Sonia Hernandez-Diaz
Journal:  JAMA       Date:  2015-06-02       Impact factor: 56.272

Review 2.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

3.  SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn.

Authors:  Anick Bérard; Odile Sheehy; Jin-Ping Zhao; Évelyne Vinet; Sasha Bernatsky; Michal Abrahamowicz
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

Review 4.  Factors relating caesarean section to persistent pulmonary hypertension of the newborn.

Authors:  Niralee Babooa; Wen-Jing Shi; Chao Chen
Journal:  World J Pediatr       Date:  2017-10-20       Impact factor: 2.764

5.  Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Authors:  Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-08       Impact factor: 5.464

6.  Mother-infant antidepressant concentrations, maternal depression, and perinatal events.

Authors:  Dorothy Sit; James M Perel; Stephen R Wisniewski; Joseph C Helsel; James F Luther; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2011-07       Impact factor: 4.384

Review 7.  Antidepressant use in pregnant and postpartum women.

Authors:  Kimberly A Yonkers; Katherine A Blackwell; Janis Glover; Ariadna Forray
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 8.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence.

Authors:  Sura Alwan; Jan M Friedman; Christina Chambers
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 9.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

10.  Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn.

Authors:  Cassidy Delaney; Jason Gien; Gates Roe; Nicole Isenberg; Jenai Kailey; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-19       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.